The move marks a rare action by the FDA to sanction a study on cannabis despite the plant’s current Schedule I classification under federal law as a drug with no therapeutic use, in the same bucket as heroin and LSD.
The move marks a rare action by the FDA to sanction a study on cannabis despite the plant’s current Schedule I classification under federal law as a drug with no therapeutic use, in the same bucket as heroin and LSD.